Atherosclerotic cardiovascular disease (ASCVD) is epidemic throughout the world and is
etiologic for such acute cardiovascular events as myocardial infarction, ischemic stroke�…

The thesis advanced here is that we are initiating treatment of hypercholesterolemia (and
other risk factors) too late in life. Initiating treatment at, for example, age 30 years instead of�…

Primary prevention of incident atherosclerotic cardiovascular disease (ASCVD) as well as
decreasing the risk of future events in those with established atherosclerosis is critical from a�…

Atherosclerotic cardiovascular disease (ASCVD) events, including coronary heart disease
and stroke, are the most frequent cause of death and major disability in the world. Current�…

Cumulative exposure to low-density lipoprotein cholesterol (LDL-C) is a key driver of
atherosclerotic cardiovascular disease (ASCVD) risk. An armamentarium of therapies to�…

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in the United
States. Elevated low-density lipoprotein cholesterol (LDL-C) is a major causal risk factor for�…

Thrombotic events caused by atherosclerosis are by far the most common cause of death in
the world. Advances in treatment have prolonged the life of patients with atherosclerotic�…

Strategies to reduce cardiovascular risk in primary and secondary prevention focus on
optimization of low-density lipoprotein (LDL) cholesterol levels. Since the 2004 update of the�…

The preponderance of evidence confirms the importance of aggressive lipid modification in
patients at risk for coronary heart disease (CHD). However, data suggest that this�…

Atherosclerosis causes nearly 75% of cardiovascular-related deaths and is found in 80% to
90% of adults≥ 30 years old in the United States. Successful treatment minimizes lifetime�…